RhumbLine Advisers
BCLI

RhumbLine Advisers’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

RhumbLine Advisers’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,882
Closed -$108K – 2996
2021
Q1 		$108K Hold
1,882
– – ﹤0.01% 2927
2020
Q4 		$128K Buy
1,882
+131
+7% +$17.8K ﹤0.01% 2937
2020
Q3 		$444K Sell
1,751
-176
-9% -$36K ﹤0.01% 2340
2020
Q2 		$324K Buy
+1,927
New +$208K ﹤0.01% 2540

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RhumbLine Advisers's BCLI Position: Q2 2021 in Review

RhumbLine Advisers sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 1,882 shares — an estimated $108K sold.

RhumbLine Advisers first reported a position in BCLI in Q2 2020 and held it in 4 quarters. The position peaked at $444K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • RhumbLine Advisers reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 1,882 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $108K.
  • RhumbLine Advisers first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 4 quarters.
  • RhumbLine Advisers's BRAINSTORM CELL THERAPUTC position peaked at $444K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.